NEW YORK, Nov. 6, 2012 /PRNewswire/ -- The physicians of Reproductive Medicine Associates of New York (RMA of New York) are proud to support The American Society for Reproductive Medicine (ASRM) in their recent decision to lift oocyte cryopreservation from its previous "experimental" label. Analyzing over 1,000 relevant research papers, ASRM has concluded that the rates of implantation and pregnancy using frozen eggs are similar to those of fresh eggs; in light of their findings, the researchers of ASRM have concluded that oocyte cryopreservation can no longer be considered an experimental treatment.
"This is beyond exciting, as it opens numerous doors for women in terms of future fertility," says Dr. Alan Copperman, Co-Medical Director of RMA of New York. "With egg freezing now becoming a main stream reproductive option, we can now offer the treatment and deliver hope to even more women."
Oocyte cryopreservation, more commonly known as egg freezing, is the process of extracting, freezing and storing a woman's eggs, typically for the purpose of safeguarding child-rearing options for a later time. The physicians of RMA of New York attribute the success of their egg freezing program to their state of the art laboratory and the highly specialized freezing technique called oocyte vitrification, a process of rapid-freezing that prevents ice crystals from forming within the oocyte and appears to improve oocyte survival rates.
There are numerous situations in which freezing eggs may be beneficial for women. RMA of New York offers egg freezing to those at risk of becoming sterile due to chemotherapy, radiotherapy or removal of their ovaries. In addition, the scientific team at RMA of NY is performing research to determine whether a woman is at risk of early menopause and to assess who could potentially most benefit from the technology.
About Reproductive Medicine Associate